UOC
KNSA icon

UBS O'Connor’s Kiniksa Pharmaceuticals KNSA Stock Holding History

UBS O'Connor’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,602
Closed -$1.04M – 381
2025
Q2 		$1.04M Sell
37,602
-101,673
-73% -$2.59M 0.03% 212
2025
Q1 		$3.09M Buy
139,275
+39,643
+40% +$816K 0.07% 91
2024
Q4 		$1.97M Buy
99,632
+24,463
+33% +$558K 0.05% 159
2024
Q3 		$1.88M Sell
75,169
-38,826
-34% -$946K 0.05% 185
2024
Q2 		$2.13M Buy
113,995
+19,500
+21% +$365K 0.06% 184
2024
Q1 		$1.86M Sell
94,495
-6,227
-6% -$122K 0.05% 185
2023
Q4 		$1.77M Sell
100,722
-5,701
-5% -$93.7K 0.06% 188
2023
Q3 		$1.85M Sell
106,423
-115,000
-52% -$1.94M 0.03% 257
2023
Q2 		$3.12M Buy
221,423
+5,213
+2% +$69.8K 0.07% 186
2023
Q1 		$2.33M Buy
216,210
+59,248
+38% +$781K 0.06% 290
2022
Q4 		$2.35M Buy
156,962
+16,000
+11% +$233K 0.04% 421
2022
Q3 		$1.81M Buy
+140,962
New +$1.61M 0.02% 652

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS O'Connor's KNSA Position: Q3 2025 in Review

UBS O'Connor sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 37,602 shares — an estimated $1.04M sold.

UBS O'Connor first reported a position in KNSA in Q3 2022 and held it in 12 quarters. The position peaked at $3.12M in Q2 2023. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

  • UBS O'Connor reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 37,602 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $1.04M.
  • UBS O'Connor first reported a position in Kiniksa Pharmaceuticals in Q3 2022 and held it in 12 quarters.
  • UBS O'Connor's Kiniksa Pharmaceuticals position peaked at $3.12M in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.